MGC products to be distributed by premier retailer, Harvey Nichols

|

Published 12-JUN-2018 15:35 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

MGC Pharmaceuticals Ltd’s (ASX:MXC) has announced that 18 products from its MGC Derma collection are to be launched in June at UK retailer, Harvey Nichols.

This is a premier luxury fashion and beauty retailer renowned for sourcing new and innovative products.

MGC Pharmaceuticals managing director Roby Zomer said: “We are excited to see the MGC Derma collection gaining such traction with premium retail platforms internationally.

“Harvey Nichols is known for its strict selection of brands and we feel we are well positioned alongside some of the industry’s leading products.”

We should note that it remains to be seen how much of the market MXC will be able to attract at this stage, so investors should seek professional financial advice if considering this stock for their portfolio.

Founded in 1831, Harvey Nichols has stores in major cities in the UK, including London.

Outside of the UK, international stores include Riyadh, Hong Kong, Dubai, Istanbul, Doha, Ankara and Kuwait.

MGC pharma harvey nichols

Promising test results provide market acceptance

MGC Derma and Derma Plus cosmetic products cosmetic products contain cannabidiol (CBD), developed and produced by MGC Pharma for its cosmetics division.

In the course of independent testing, the three products tested showed strong improvement in skin conditions, relieving redness, dryness, flaky and oily indications for acne related symptoms or skin prone to blemishes.

Following the results, 92% of patients continued using the tested cream.

MGC products to be given prominent position

Commencing June 29, 2018 MGC’s products will be sold on the ground floor of the Beyond Beauty department within Knightsbridge and its e-commerce stores at luxury retailer Harvey Nichols.

After release of the news, share price was up 5% in early morning trading.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

Importantly, this deal will provide immediate revenue generation, while also broadening consumer awareness.

Management is planning a targeted marketing program to take advantage of this momentum.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X